Healthcare / Diagnostics & ResearchParis
$71.50
-2.85 (-3.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $321.5M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
21.4x
↑EV/EBITDA
9.8x
↓ROE
9.7%
↑Gross Margin
56.7%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.3%
FCF CAGR
+34.0%
FCF margin
11.1%
FCF / Net income
1.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.07B · net income $397.5M · FCF $453.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.07B | $4.07B | $3.98B | $3.67B | $3.59B |
| Net Income | $397.5M | $397.5M | $432.2M | $357.6M | $452.4M |
| EBITDA | $848.6M | $848.6M | $897.5M | $712.2M | $832.6M |
| EPS | — | — | 3.64 | 3.01 | 3.82 |
| Gross Margin | 56.7% | 56.7% | 55.7% | 56.0% | 56.0% |
| Operating Margin | 17.1% | 17.1% | 16.0% | 15.5% | 17.4% |
| Net Margin | 9.8% | 9.8% | 10.9% | 9.7% | 12.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.12 | 0.14 | 0.14 |
| Current Ratio | 2.39 | 2.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $453.1M | $453.1M | $321.5M | $107.1M | $188.4M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 10.3% | 9.5% | 12.6% |
| Valuation | |||||
| P/E | 21.41 | 21.41 | 28.05 | 32.54 | 25.31 |
| EV/EBITDA | 9.81 | 9.81 | 13.56 | 16.57 | 13.70 |
| P/B | 2.06 | 2.06 | 2.88 | 3.10 | 3.18 |
| Growth & Yield | |||||
| Revenue Growth | 2.3% | 2.3% | 8.3% | 2.4% | — |
| EPS Growth | — | — | 20.9% | -21.2% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-39.3%
Start / end P/E
n/dx → n/dx
EPS bridge
3.64 → n/d
Residual
-40.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.